This Program Grant has three investigators, Professor Denis Moss, Dr Rajiv Khanna and Dr Scott Burrows, each of whom has collaborated on two previous Program Grants. The group is well known in the area of herpesvirus immunology and have published numerous scientific papers in leading medical journals. This program grant focuses on two human herpesviruses. The first is called Epstein-Barr virus which causes glandular fever and is associated with arange of human cancers. The second virus is human ....This Program Grant has three investigators, Professor Denis Moss, Dr Rajiv Khanna and Dr Scott Burrows, each of whom has collaborated on two previous Program Grants. The group is well known in the area of herpesvirus immunology and have published numerous scientific papers in leading medical journals. This program grant focuses on two human herpesviruses. The first is called Epstein-Barr virus which causes glandular fever and is associated with arange of human cancers. The second virus is human cytomegalovirus which can cause birth defects and problems in transplant patients. In this program we are investigating how the body�s immune system controls these viruses to exploit this information to develop new treatments.Read moreRead less
While current influenza vaccines blunt winter epidemics, they must be updated frequently to keep up with virus mutation and they do not protect against pandemics caused by new flu viruses (such as bird flu). This program will define how flu virus interacts with the immune system to generate immunity mediated particularly by “killer” T cells. We will use this knowledge to develop and evaluate vaccines that induce long-lasting T-cell immunity that can protect against both seasonal and pandemic flu ....While current influenza vaccines blunt winter epidemics, they must be updated frequently to keep up with virus mutation and they do not protect against pandemics caused by new flu viruses (such as bird flu). This program will define how flu virus interacts with the immune system to generate immunity mediated particularly by “killer” T cells. We will use this knowledge to develop and evaluate vaccines that induce long-lasting T-cell immunity that can protect against both seasonal and pandemic flu.Read moreRead less
Immunological Therapies For Cancer, Chronic Infection And Autoimmunity
Funder
National Health and Medical Research Council
Funding Amount
$10,891,788.00
Summary
The team comprises five leading scientists with a history of successful investigation into the role of the immune system in cancers, chronic viral infections, and autoimmune diseases. There is a large unmet need for effective solutions with fewer side effects in these diseases which cause a high disease burden in our society. In this program, we particularly seek to develop novel vaccines for chronic infections and autoimmune diseases, and to improve the safety of bone marrow transplantation.
Roles Of Impaired Apoptosis And Differentiation In Tumourigenesis And Therapy
Funder
National Health and Medical Research Council
Funding Amount
$21,656,910.00
Summary
The ten scientific laboratories in this program have joined forces to investigate two ways in which tumours develop. Both are of particular interest, because they suggest new ways in which cancer might be overcome. Most of our tissues are continually renewed throughout life by production of new cells. Therefore many of the old cells in each tissue must die off to maintain the proper cell numbers. To eliminate cells that are no longer needed or have become damaged, the body has developed a remark ....The ten scientific laboratories in this program have joined forces to investigate two ways in which tumours develop. Both are of particular interest, because they suggest new ways in which cancer might be overcome. Most of our tissues are continually renewed throughout life by production of new cells. Therefore many of the old cells in each tissue must die off to maintain the proper cell numbers. To eliminate cells that are no longer needed or have become damaged, the body has developed a remarkable cell suicide process termed apoptosis. Unfortunately, however, occasionally a random accident to the genes in one of our cells prevents the machinery for apoptosis from being turned on. In that case, the cell will not die when it should and, by continually dividing, it may eventually give rise to a cancer. Since most cancer cells still retain most of the machinery for apoptosis, however, a drug that could switch on this natural cell death machinery would provide a promising new approach to cancer therapy. Identifying and developing such drugs is one major long-term goal of this program. The other focus of our program concerns stem cells. These are rare cells with the remarkable ability to generate an entire tissue. For example, one of our laboratories has identified stem cells that can generate all the cells in the breast. The almost unlimited regenerative capacity of stem cells has a built-in danger. If a stem cell acquires the ability to proliferate excessively, it can go on to form a tumour. Indeed, many cancer researchers now suspect that rare stem cells within a tumour cause its inexorable growth. If tumour growth is maintained by stem cells, it will be essential to develop new forms of therapy that target these rare cancer stem cells rather than merely the bulk of the tumour cells. This is another key long-term goal of our program.Read moreRead less
Control Of Cell Proliferation And Differentiation In Breast And Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$5,043,011.00
Summary
Breast and prostate cancer are the most commonly diagnosed cancers in women and men respectively, together accounting for >25% of all newly diagnosed cancers in Australia and other developed countries. Although significant improvements in the management of these cancers have occurred in the past 20 years further research is needed to better understand the molecular mechanisms of disease development and progression. Such research is critical to the better management and ultimate control of the ....Breast and prostate cancer are the most commonly diagnosed cancers in women and men respectively, together accounting for >25% of all newly diagnosed cancers in Australia and other developed countries. Although significant improvements in the management of these cancers have occurred in the past 20 years further research is needed to better understand the molecular mechanisms of disease development and progression. Such research is critical to the better management and ultimate control of these diseases through better treatments and prevention. A multidisciplinary team of cancer researchers at the Garvan Institute of Medical Research, with a 10 year track record of discovery and application of their research into breast and prostate cancer, will employ state-of-the-art research tools to identify new molecules and molecular pathways involved in these diseases. This new information will facilitate the improved management of these cancers through improved assessment of disease progression at the time of diagnosis and the development of new drugs and strategies for treatment and prevention.Read moreRead less
Molecular Markers Of Phenotype, Therapeutic Responsiveness And Prognosis In Human Cancers.
Funder
National Health and Medical Research Council
Funding Amount
$11,762,117.00
Summary
This proposal aims to identify molecular markers that can be used to classify subtypes of particular cancers according to their prognosis and response to therapy. This will optimise selection of patients for the most appropriate treatment and lead to the development of new therapeutic strategies.
Molecular Determinants Of Risk, Progression And Treatement Response In Melenoma
Funder
National Health and Medical Research Council
Funding Amount
$12,947,193.00
Summary
Melanoma is a major Australian health problem. It is the third most common cancer in men and women and has a disproportionately heavy impact on productive years of life because it is the common cause of cancer death in younger adults. The investigators are all associated with the Melanoma Institute Australia, incorporating the Sydney Melanoma Unit (SMU). MIA is the world’s largest clinical service dedicated to the treatment of melanoma, treating >1500 new melanoma patients annually and mainta ....Melanoma is a major Australian health problem. It is the third most common cancer in men and women and has a disproportionately heavy impact on productive years of life because it is the common cause of cancer death in younger adults. The investigators are all associated with the Melanoma Institute Australia, incorporating the Sydney Melanoma Unit (SMU). MIA is the world’s largest clinical service dedicated to the treatment of melanoma, treating >1500 new melanoma patients annually and maintains a repository of clinical data on melanoma and a large melanoma tissue bank. The Program has also recruited large numbers of people from the community, as well as people with a strong family history of melanoma, in order to study its causes. It aims to utilise these internationally-recognised resources to develop a scientific basis for 1) improved management of individuals at high risk for development and progression of melanoma, and 2) improved treatment of patients with early and disseminated melanoma, in an era of rapid change in the prospects of successfully treating this dangerous cancer. The Program will do this by consolidating and extending its existing collaborative research, supported by NHMRC since 2006.Read moreRead less
Gynaecological, Oesophageal And Skin Cancer In Australia: Developing The Evidence-base
Funder
National Health and Medical Research Council
Funding Amount
$6,079,935.00
Summary
Our Program addresses cancers of the ovary, uterus, oesophagus and skin (both melanoma and non-melanoma skin cancers). The first three cancers together affect almost 4,000 people and cause more than 2,000 deaths every year while skin cancer affects almost 400,000 Australians each year. Our aims are, first, to understand better how these cancers are caused so that we can try to prevent them in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and qualit ....Our Program addresses cancers of the ovary, uterus, oesophagus and skin (both melanoma and non-melanoma skin cancers). The first three cancers together affect almost 4,000 people and cause more than 2,000 deaths every year while skin cancer affects almost 400,000 Australians each year. Our aims are, first, to understand better how these cancers are caused so that we can try to prevent them in the future; second, to enhance diagnosis of these cancers; and third, to improve the survival and quality of life for people who are diagnosed with these cancers in Australia.Read moreRead less